Melhem Solh

6.3k citations

136 papers · 2.1k indexed · 1 hit paper · h-index 26

Impact in

Hematology top 1%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
Oncology top 2%
- CAR-T cell therapy research

Papers in ⓘ

Hematology 85
- Hematopoietic Stem Cell Transplantation 56
- Acute Myeloid Leukemia Research 22
- Multiple Myeloma Research and Treatments 21
Transplantation 13

Co-authors: Asad Bashey (57 shared papers)Lawrence E. Morris (56 shared papers)Scott R. Solomon (55 shared papers)H. Kent Holland (53 shared papers)Mehdi Hamadani (21 shared papers)Paolo F. Caimi (20 shared papers)Kirit M. Ardeshna (21 shared papers)Brad S. Kahl (20 shared papers)
Journals: Blood (36 papers)Biology of Blood and Marrow Transplantation (24 papers)Journal of Clinical Oncology (10 papers)Blood Advances (9 papers)Bone Marrow Transplantation (7 papers)
Partner nations: United States United Kingdom Italy

In The Last Decade

Melhem Solh

127 papers receiving 2.1k citations

Hit Papers

align trajectories log scale

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial 2021 · 264 citations

Peers

Countries citing papers authored by Melhem Solh

Since Specialization

Citations

This map shows the geographic impact of Melhem Solh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melhem Solh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melhem Solh more than expected).

Fields of papers citing papers by Melhem Solh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melhem Solh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melhem Solh. The network helps show where Melhem Solh may publish in the future.

Co-authors

The 25 scholars most cited alongside Melhem Solh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Melhem Solh Line = papers co-authored together Melhem Solh links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 136 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial The Lancet Oncology ·Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani, Brian Hess, Brad S. Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Karin Havenith, Jay Feingold, Shui He, Yajuan Qin, David Ungar, Xiaoyan Zhang, Carmelo Carlo‐Stella Hit paper breakdown →	2021	264
2	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma Blood ·Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl	2020	122
3	Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index Biology of Blood and Marrow Transplantation ·Asad Bashey, Xu Zhang, Katelin C Jackson, Stacey Brown, Michelle Ridgeway, Melhem Solh, Lawrence E. Morris, H. Kent Holland, Scott R. Solomon	2015	105
4	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Clinical Cancer Research ·Brad S. Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Jay Feingold, Kirit M. Ardeshna, Melhem Solh, Leonard T. Heffner, David Ungar, Shui He, Joseph Boni, Karin Havenith, Owen A. O’Connor	2019	77
5	Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial Nature Medicine ·Nizar J. Bahlis, Caitlin Costello, Noopur Raje, Moshe Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H. Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M. Chan, Suzanne Trudel, Andrzej Jakubowiak, Cristina Gasparetto, Michael P. Chu, Andrew Dalovisio, Michaël Sébag, Alexander M. Lesokhin	2023	76
6	Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment Cytotherapy ·Jeremiah L. Oyer, Veethika Pandey, Robert Y. Igarashi, Srinivas S. Somanchi, Ahmed Zakari, Melhem Solh, Dean A. Lee, Deborah A. Altomare, Alicja J. Copik	2016	70
7	Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options Journal of Blood Medicine ·Melhem Solh, Tia Solh, Ashley Botsford	2015	65
8	Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach Biology of Blood and Marrow Transplantation ·Jeremiah L. Oyer, Robert Y. Igarashi, Alexander R. Kulikowski, Dominic A. Colosimo, Melhem Solh, Ahmed Zakari, Yasser Khaled, Deborah A. Altomare, Alicja J. Copik	2015	62
9	Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables Biology of Blood and Marrow Transplantation ·Scott R. Solomon, Michael T. Aubrey, Xu Zhang, Allison Piluso, Brian M. Freed, Stacey Brown, Katelin C Jackson, Lawrence E. Morris, H. Kent Holland, Melhem Solh, Asad Bashey	2018	61
10	Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse Biology of Blood and Marrow Transplantation ·Melhem Solh, Todd E. DeFor, Daniel J. Weisdorf, Dan S. Kaufman	2011	57
11	Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide Blood Advances ·Shannon R. McCurdy, Mei-Jie Zhang, Andrew St. Martin, Monzr M. Al Malki, Asad Bashey, Sameh Gaballa, Daniel A. Keesler, Mehdi Hamadani, Maxim Norkin, Miguel‐Angel Perales, Ran Reshef, Vanderson Rocha, Rizwan Romee, Melhem Solh, Álvaro Urbano-Ispizúa, Edmund K. Waller, Ephraim J. Fuchs, Mary Eapen	2018	55
12	CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy Blood Advances ·Bicky Thapa, Paolo F. Caimi, Kirit M. Ardeshna, Melhem Solh, Carmelo Carlo‐Stella, Brad S. Kahl, Mehdi Hamadani	2020	47
13	Extramedullary acute myelogenous leukemia Blood Reviews ·Melhem Solh, Scott R. Solomon, Lawrence E. Morris, Kent Holland, Asad Bashey	2016	45
14	Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy American Journal of Hematology ·Melhem Solh, Sophia Yohe, Daniel Weisdorf, Celalettin Üstün	2014	43
15	Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1 Blood ·Michaël Sébag, Noopur Raje, Nizar J. Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Levy, Michael H. Tomasson, Harman Dube, Michael A. Damore, Hoi Ken Lon, Cynthia Basu, Athanasia Skoura, Edward M. Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P. Chu, Cristina Gasparetto, Andrew Dalovisio, Alexander M. Lesokhin	2021	41
16	Factors Predicting Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center Biology of Blood and Marrow Transplantation ·Melhem Solh, Xu Zhang, Katelin Connor, Stacey Brown, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland, Asad Bashey	2016	38
17	Platelet and Red Blood Cell Utilization and Transfusion Independence in Umbilical Cord Blood and Allogeneic Peripheral Blood Hematopoietic Cell Transplants Biology of Blood and Marrow Transplantation ·Melhem Solh, Claudio G. Brunstein, Shanna Morgan, Daniel J. Weisdorf	2010	35
18	Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma Blood ·Noopur Raje, Nizar J. Bahlis, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Levy, Michael H. Tomasson, Michael A. Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M. Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P. Chu, Cristina Gasparetto, Andrew Dalovisio, Michaël Sébag, Alexander M. Lesokhin	2022	33
19	Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). Journal of Clinical Oncology ·Nizar J. Bahlis, Noopur Raje, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Moshe Levy, Michael H. Tomasson, Harman Dube, Feng Liu, Ken Liao, Cynthia Basu, Athanasia Skoura, Edward M. Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael P. Chu, Cristina Gasparetto, Andrew Dalovisio, Michaël Sébag, Alexander M. Lesokhin	2021	31
20	Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older Bone Marrow Transplantation ·Zain Bashey, Xu Zhang, Stacey Brown, Katelin C Jackson, Lawrence E. Morris, H. Kent Holland, Asad Bashey, Scott R. Solomon, Melhem Solh	2018	30

About Melhem Solh

Melhem Solh is a scholar working on Hematology, Transplantation, Oncology, Genetics and Immunology, having authored 136 papers that have together received 2.1k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (56 papers), CAR-T cell therapy research (41 papers), Acute Myeloid Leukemia Research (22 papers), Multiple Myeloma Research and Treatments (21 papers), Acute Lymphoblastic Leukemia research (20 papers), Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Immune Cell Function and Interaction (15 papers). The work is most often cited by research in Hematology (1.1k citations), Oncology (1.2k citations), Transplantation (101 citations), Pathology and Forensic Medicine (529 citations) and Genetics (308 citations). Melhem Solh has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Asad Bashey, Lawrence E. Morris, Scott R. Solomon, H. Kent Holland, Mehdi Hamadani, Paolo F. Caimi, Kirit M. Ardeshna, Brad S. Kahl, Carmelo Carlo‐Stella and Stacey Brown. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Journal of Clinical Oncology, Blood Advances and Bone Marrow Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact